科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行转仓市值4.32亿港元

智通财经05-20

智通财经APP获悉，香港联交所最新资料显示，5月19日，科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。

科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。

公司指出，集资净额当中约70%用于创新药在全球(含中国)的临床开发研发支出，包括异体及体内CAR-T产品的IND申报及临床试验;约15%用于全球研发及生产的设备设施开支;约15%作营运资金及一般公司用途，包括商业化团队的组建等。董事会认为，此次配股能增强集团财务实力，加快研发管线开发及适应症拓展进度，并能扩大股东基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2636893927?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-20 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636893927","market":"hk","top_or_hot":-1,"title":"科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行 转仓市值4.32亿港元","media":"智通财经","content":"<html><body><p>智通财经APP获悉，香港联交所最新资料显示，5月19日，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。</p><p>科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。</p><p>公司指出，集资净额当中约70%用于创新药在全球(含中国)的临床开发研发支出，包括异体及体内CAR-T产品的IND申报及临床试验;约15%用于全球研发及生产的设备设施开支;约15%作营运资金及一般公司用途，包括商业化团队的组建等。董事会认为，此次配股能增强集团财务实力，加快研发管线开发及适应症拓展进度，并能扩大股东基础。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行 转仓市值4.32亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行 转仓市值4.32亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，香港联交所最新资料显示，5月19日，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。</p><p>科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。</p><p>公司指出，集资净额当中约70%用于创新药在全球(含中国)的临床开发研发支出，包括异体及体内CAR-T产品的IND申报及临床试验;约15%用于全球研发及生产的设备设施开支;约15%作营运资金及一般公司用途，包括商业化团队的组建等。董事会认为，此次配股能增强集团财务实力，加快研发管线开发及适应症拓展进度，并能扩大股东基础。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1443721.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0162691827.USD","symbol_name":"BGF US BASIC VALUE \"A4\" INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1443721.html","article_id":"2636893927","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636893927","pubTimestamp":1779235706,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，科济药业-B股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4566":"资本集团","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK1161":"生物科技","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","BK4588":"碎股","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4504":"桥水持仓","BK4207":"综合性银行","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK1574":"生物医药B类股","BK4559":"巴菲特持仓","BK1587":"次新股","BK4534":"瑞士信贷持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","02171":"科济药业-B","LU0106831901.USD":"贝莱德世界金融基金A2","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","BK1585":"昨日强势股","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H"},"translate_title":"Shareholders of Keji Pharmaceutical-B (02171) transferred shares from UBS Securities Hong Kong to Citibank with a market value of HK$432 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1.5},"content_text":"智通财经APP获悉，香港联交所最新资料显示，5月19日，科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。公司指出，集资净额当中约70%用于创新药在全球(含中国)的临床开发研发支出，包括异体及体内CAR-T产品的IND申报及临床试验;约15%用于全球研发及生产的设备设施开支;约15%作营运资金及一般公司用途，包括商业化团队的组建等。董事会认为，此次配股能增强集团财务实力，加快研发管线开发及适应症拓展进度，并能扩大股东基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636893927","isCrawlerRequest":true}

科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行 转仓市值4.32亿港元

精彩评论

科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行转仓市值4.32亿港元